Aakaar Medical Technologies Share Price

Aakaar Medical Technologies Limited was originally incorporated as Aakaar Medical Technologies Private Limited', a private limited company dated June 20, 2013 issued by the Registrar of Companies, Mumbai. Subsequently, Company status was converted into a public limited company and a fresh certificate of incorporation dated November 18, 2024 was issued by the Registrar of Companies, Mumbai, recording the change in the name of Company to Aakaar Medical Technologies Limited'. Incorporated in 2013, Aakaar Medicals are a medical aesthetic company dealing in a wide range of aesthetics & specialised cosmetic products & devices. The Company supply its products & devices primarily to aesthetic physicians such as dermatologists, plastic surgeons, aesthetic physicians who sell these products to end consumers as well as use certain device consumables as part of their treatments. The product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. In October 2016, Company entered into licensing, marketing and distribution agreement with Medytox Inc., South Korea for launch of Siax. In June 2017, it launched own brands Tubelite; launched Balback brand in July, 2017, launched Lytec brand in December 2017; launched Etrelume brand in Oct' 22; launched Swyada brand in August, 2023; launched Exoluxe and DRS1512 brands in August, 2024; launched Eoluxe in September, 2024. Company has launched the initial public offer by issuing 37,50,400 equity shares of Rs 10 each by raising funds aggregating to Rs 27 Crore in June, 2025 through fresh issue. A strategic clinic partnership and network expansion initiative under Xelix Clinics was launched in January 2026. The Company launched Letybo, Saypha (now USFDA-approved), the VM Corp exosome suite, and XOMAGE plant exosomes in FY26.